The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Alternative non-antibody scaffolds for molecular recognition
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bès, C., Troadec, S., Chentouf, M., Breton, H., Lajoix, A., Heitz, F., Gross, R., Plückthun, A., & Chardès, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.126 · Cited by 8
RetractedEngineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Targeting and tracing antigens in live cells with fluorescent nanobodies
Rothbauer, U., Zolghadr, K., Tillib, S., Nowak, D., Schermelleh, L., Gahl, A., Backmann, N., Conrath, K., Muyldermans, S., Cardoso, M. C., et al. (2006) · Nature Methods · doi:10.1038/nmeth953 · Cited by 710
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
High-affinity binders selected from designed ankyrin repeat protein libraries
Binz, H. K., Amstutz, P., Kohl, A., Stumpp, M. T., Briand, C., Forrer, P., Grütter, M. G., & Plückthun, A. (2004) · Nature Biotechnology · doi:10.1038/nbt962 · Cited by 656
Analyzing antibody specificity with whole proteome microarrays
Michaud, G. A., Salcius, M., Zhou, F., Bangham, R., Bonin, J., Guo, H., Snyder, M., Predki, P. F., & Schweitzer, B. I. (2003) · Nature Biotechnology · doi:10.1038/nbt910 · Cited by 277
Directed Evolution of High-Affinity Antibody Mimics Using mRNA Display
Xu, L., Aha, P., Gu, K., Kuimelis, R. G., Kurz, M., Lam, T., Lim, A. C., Liu, H., Lohse, P. A., Sun, L., et al. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00187-4 · Cited by 251
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
Silverman, J., Lu, Q., Bakker, A., To, W., Duguay, A., Alba, B. M., Smith, R., Rivas, A., Li, P., Le, H., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1166 · Cited by 237
Engineered protein scaffolds for molecular recognition
Skerra, A. (2000) · Journal of Molecular Recognition · doi:10.1002/1099-1352(200007/08)13:4<167::aid-jmr502>3.0.co;2-9 · Cited by 236
Self-citationTaussig, M. J., Stoevesandt, O., Borrebaeck, C. A. K., Bradbury, A. R., Cahill, D., Cambillau, C., de Daruvar, A., Dübel, S., Eichler, J., Frank, R., et al. (2007) · Nature Methods · doi:10.1038/nmeth0107-13 · Cited by 236
Self-citationTolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandström, M., Rosik, D., Carlsson, J., Lundqvist, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1630 · Cited by 220
Binding proteins from alternative scaffolds
Nygren, P.-Å., & Skerra, A. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.006 · Cited by 218
Self-citationSteiner, D., Forrer, P., Stumpp, M. T., & Plückthun, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1218 · Cited by 213
A new generation of protein display scaffolds for molecular recognition
Hosse, R. J., Rothe, A., & Power, B. E. (2006) · Protein Science · doi:10.1110/ps.051817606 · Cited by 211
Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes
Martin, L., Stricher, F., Missé, D., Sironi, F., Pugnière, M., Barthe, P., Prado-Gotor, R., Freulon, I., Magne, X., Roumestand, C., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt768 · Cited by 188
Lipocalins in drug discovery: From natural ligand-binding proteins to ‘anticalins’
Schlehuber, S., & Skerra, A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03294-5 · Cited by 171
Self-citationEngineered proteins as specific binding reagents
Binz, H. K., & Plückthun, A. (2005) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2005.06.005 · Cited by 157
Handbook of Therapeutic Antibodies
(2007) · Wiley eBooks · doi:10.1002/9783527619740 · Cited by 145
Affibody molecules: potential forin vivoimaging of molecular targets for cancer therapy
Максимилианович, Т. В., Orlova, A., Nilsson, F. Y., Feldwisch, J., Wennborg, A., & Abrahmsén, L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.555 · Cited by 143
Economic aspects of commercial manufacture of biopharmaceuticals
Werner, R. G. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.04.036 · Cited by 142
Amstutz, P., Binz, H. K., Parizek, P., Stumpp, M. T., Kohl, A., Grütter, M. G., Forrer, P., & Plückthun, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501746200 · Cited by 137
Artificial, non-antibody binding proteins for pharmaceutical and industrial applications
Hey, T., Fiedler, E., Rudolph, R., & Fiedler, M. R. M. (2005) · Trends in biotechnology · doi:10.1016/j.tibtech.2005.07.007 · Cited by 136
Koide, A., Abbatiello, S., Rothgery, L., & Koide, S. (2002) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.032665299 · Cited by 132
Lipovšek, D., Lippow, S. M., Hackel, B. J., Gregson, M. W., Cheng, P. P., Kapila, A., & Wittrup, K. D. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.029 · Cited by 123
Schlehuber, S., Beste, G., & Skerra, A. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3646 · Cited by 115
Self-citationIn vitro display technologies reveal novel biopharmaceutics
Rothe, A., Hosse, R. J., & Power, A. B. E. (2006) · The FASEB Journal · doi:10.1096/fj.05-5650rev · Cited by 105
DX-88 and HAE: a developmental perspective
Williams, A. H., & Baird, L. G. (2003) · Transfusion and Apheresis Science · doi:10.1016/s1473-0502(03)00170-8 · Cited by 100
Getmanova, E. V., Chen, Y., Bloom, L., Gokemeijer, J., Shamah, S. M., Warikoo, V., Wang, J., Ling, V., & Sun, L. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.12.009 · Cited by 100
Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain
Koide, A., & Koide, S. (2006) · Humana Press eBooks · doi:10.1385/1-59745-187-8:95 · Cited by 98
Immunogenicity screening in protein drug development
Walle, I. V., Gansemans, Y., Parren, P. W. H. I., Stas, P., & Lasters, I. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.405 · Cited by 87
Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries
Amstutz, P., Koch, H., Binz, H. K., Deuber, S. A., & Plückthun, A. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl004 · Cited by 77
A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Properties
Grabulovski, D., Kaspar, M., & Neri, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609211200 · Cited by 75
Biopharmaceutical drug discovery using novel protein scaffolds
Gill, D. S., & Damle, N. K. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.003 · Cited by 67
Wiederstein, M., & Sippl, M. J. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.11.012 · Cited by 61
Imitating the humoral immune response
Skerra, A. (2003) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2003.10.012 · Cited by 57
Self-citationAttucci, S., Gauthier, A., Korkmaz, B., Delépine, P., Martino, M., Saudubray, F., Diot, P., & Gauthier, F. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103440 · Cited by 57
Peptide aptamers: recent developments for cancer therapy
Borghouts, C., Kunz, C., & Groner, B. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.6.783 · Cited by 47
Rönnmark, J., Kampf, C., Asplund, A., Höidén‐Guthenberg, I., Wester, K., Pontén, F., Uhlén, M., & Nygren, P. (2003) · Journal of Immunological Methods · doi:10.1016/j.jim.2003.06.001 · Cited by 36
Directed Evolution of ATP Binding Proteins from a Zinc Finger Domain by Using mRNA Display
Cho, G. S., & Szostak, J. W. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.10.015 · Cited by 35
Rational engineering of a fluorescein-binding anticalin for improved ligand affinity
Vopel, S., Mohr, H., & Skerra, A. (2005) · Biological Chemistry · doi:10.1515/bc.2005.126 · Cited by 29
Self-citationHohlbaum, A. M., & Skerra, A. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.4.491 · Cited by 25
Self-citationFiedler, M. R. M., & Skerra, A. (2007) · Wiley eBooks · doi:10.1002/9783527619740.ch20 · Cited by 4
Self-citation
Cited by
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Beyond natural antibodies: the power of in vitro display technologies
Bradbury, A. R. M., Sidhu, S., Dübel, S., & McCafferty, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1791 · Cited by 545
Structural and thermodynamic analysis of the GFP:GFP‐nanobody complex
Kubala, M. H., Kovtun, O., Alexandrov, K., & Collins, B. M. (2010) · Protein Science · doi:10.1002/pro.519 · Cited by 400
Nucleic Acid and Peptide Aptamers: Fundamentals and Bioanalytical Aspects
Mascini, M., Palchetti, I., & Tombelli, S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201006630 · Cited by 374
Metadata
- Authors
- Skerra, A.
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 18
- Issue
- 4
- Pages
- 295-304
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W2065620086
- Cited by
- 300
- References
- 44
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.